Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AyoxxA Biosystems Closes Series A Financing Round

Published: Thursday, September 20, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
2.6 million Euro financing will accelerate development of cutting-edge technology for protein analysis.

AyoxxA Biosystems has announced that it has closed a 2.6 million Euro Series A financing round.

The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.

The funds raised will be used to drive the further development of AyoxxA’s proprietary platform technology and the scale-up of production of its novel bead-based biochips as the company moves towards commercialization.

AyoxxA’s technology is aimed at transforming the throughput and accuracy of protein analysis to deliver the analytical power now seen only for DNA arrays.

The platform is based around proprietary In-situ Encoded Bead-based Arrays (IEBA) which allow the simultaneous measurement of multiple proteins from minute samples.

Unlike current bead-based microarrays, AyoxxA’s IEBA need no physical label to allow multiplex analysis and thus hugely reduce the complexity of downstream analysis while increasing the number of individual proteins that can be analyzed at the same time.

The arrays are designed to be readily adaptable to standard high throughput screening systems and offer the potential of tens of thousands of ELISA assays in a single well of a biochip.

Dr. Andreas Schmidt, CEO of AyoxxA, said: “This fundraising provides Ayoxxa with the resources to significantly accelerate the scale-up of production of our unique bead-based biochips and, through the expansion of our base in Cologne, prepare to bring our technology to market. We believe our technology can revolutionize protein analysis and with our growing presence in Europe combined with our continued access to the world-class science in Singapore we are uniquely positioned to deliver on that promise.”

Dr. Regina Hodits, General Partner of Wellington Partners Venture Capital, commented: “AyoxxA’s technology has the potential to become the new standard for the precise, fast, and cost effective analysis of multiple protein-protein interactions in limited sample volumes. This will allow the company to initially address a research market worth hundreds of millions of dollars and longer term reach into pharmaceutical screening and ultimately diagnostics. In Andreas Schmidt and co-founder and CSO Dieter Trau, we have a very entrepreneurial team which has already rapidly brought the AyoxxA technology from the idea stage to first proof-of-concept. We look forward to working with the company as it builds on this excellent foundation and delivers benefits to its customers and investors.”

Rainer Christine, Chairman of the Board of AyoxxA, said: “It is exciting to be investing in AyoxxA at a critical point in the Company’s development. I have followed its story closely since it was founded by Andreas and Dieter, who had invented the technology as a Professor of Bioengineering at the National University of Singapore. I am impressed by the progress made in advancing the technology and by the potential it has to address significant markets. I hope to bring the experience I gained in successfully building amaxa to the Board and Company as it grows.”

Dr. Matthias Dill, HTGF investment manager, added: "We are pleased to have played a role in building a consortium of experienced investors to optimally support AyoxxA as it benefits further from its position as part of two high tech countries. The company’s choice to base its headquarters in Cologne highlights the continuing attractiveness of Germany as a site for building new companies and growing international businesses.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AYOXXA and Grünenthal Completed Research Collaboration
Successful validation of protein multiplexing technology platform.
Thursday, June 25, 2015
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!